by Stephen Albainy-Jenei
June 30, 2009
The American Conference Institute’s Maximizing Pharmaceutical Patent Lifecycles, the 10th Anniversary Edition will be held at the Helmsley Park Lane Hotel, New York, New York, on Wednesday, October 7, 2009 to Thursday, October 8, 2009.
Overview
This 10th American Conference Institute event on Maximizing Pharmaceutical Patent Life Cycles will bring you the thoughtful and targeted commentary and in-depth analysis that you have come to expect from this industry leading conference. This year’s conference will help you prepare for the sweeping changes currently underway by providing you with:
* Focused panels on the pending Follow-On Biologics and Patent Reform legislation that will allow you to assess how both legislative proposals will impact pharmaceutical patent life cycle management
* Access to key officials from the FTC’s Bureau of Competition’s Health Care Division and the EC’s DG Competition’s Pharmaceuticals Task Force who will provide you with direct insights into the logic of these agencies on some of the most pressing antitrust matters currently affecting the industry
* An in-depth review of new FDA determinations regarding exclusivity, forfeitures, patent listing and delistings and strategies for incorporating these guidelines into your initial life cycle management plan
* Analyses of key cases that have affected patent life cycle strategies and tips for using these rulings to your advantage
Read more about this conference on pharmaceutical patent lifecycles.
Pharmaceutical Patents
pharmaceutical patent
Counterfeit medicines are a major threat to public health and safety. As counterfeiting methods become more sophisticated the risk that counterfeit medicines enter the EU through illegal distribution channels increases every year. Compared to 2005 seizures of counterfeit medicines at the boarder of the EU have increased in 2007 by 380%. Fake medicines represent a serious threat to global health and call for a comprehensive strategy both at European and at international level.
The European Commission works together with European and international partners to ensure that legal methods for the marketing of medicines are respected and enforced. The Commission is an active member the International Medical Products Anti Counterfeiting Taskforce (IMPACT) created by the World Health Organisation in 2006 and has specifically co-funded and supported WHO in the development of the recommendation “Principles and Elements for National legislation against Counterfeit Medical Products“. The Commission also works together with the European Medicines Agency (EMEA) and the Council of Europe, in particular with the European Directorate for Quality of Medicines and Healthcare (EDQM) on specific questions related to counterfeit medicines.
Read the rest of this article here.
counterfeit medicines
counterfeit medicines
Counterfeits pose serious public health risks and negatively affect treatment outcomes of patients who are inadvertently administered counterfeit products. Counterfeits can kill. Even if a patient is only injured, the effects can be devastating and there is no regulatory or other recourse for the patient to obtain redress against the counterfeiter.
For more information, watch the video on the original blog post on counterfeit medicines.
counterfeit medicines
counterfeit medicines
